<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: November 20, 1998
(Date of earliest event reported)
AVANIR PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
9393 Towne Centre Drive, San Diego, California 92121
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE> 2
Item 5. OTHER EVENTS
On November 20, 1998, the Company's name changed from LIDAK
Pharmaceuticals to AVANIR Pharmaceuticals and on November 30, 1998 the Company's
securities began trading under the new symbol, AVNR, replacing the old symbol,
LDAKA. The Company's Stock trades on Nasdaq National Market System.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
AVANIR PHARMACEUTICALS
Date: December 7, 1998 By: \s\ Gregory P. Hanson
-------------------------------------------
Gregory P. Hanson
Vice President & Chief Financial Officer
